Hepatic Artery Dissection in a Patient on Bevacizumab Resulting in Pseudoaneurysm Formation

 

 Buy Article Permissions and Reprints

ABSTRACT

Interventional radiologists are frequently encountering patients with colorectal cancer that are being treated with bevacizumab. This therapeutic agent is associated with a potentially increased risk of adverse events when invasive procedures are performed while patients are on therapy. The current case report reviews a complication related to planning angiography for radioembolization with Yttrium-90 microspheres in an individual on bevacizumab and subsequent management of the patient.

REFERENCES

• 1 Gordon C R, Rojavin Y, Patel M et al.. A review on bevacizumab and surgical wound healing: an important warning to all surgeons.  Ann Plast Surg. 2009;  62 (6) 707-709
  CrossrefPubMedGoogle Scholar
• 2 Kemeny M M. How many patients and how many complications does it take to decide if a drug is safe to use before surgery?.  J Clin Oncol. 2009;  27 (11) 1917-1918, author reply 1918
  PubMedGoogle Scholar
• 3 Kesmodel S B, Ellis L M, Lin E et al.. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.  J Clin Oncol. 2008;  26 (32) 5254-5260
  CrossrefPubMedGoogle Scholar
• 4 Petrelli N J. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.  J Clin Oncol. 2009;  27 (11) 1917, author reply 1918
  PubMedGoogle Scholar
• 5 Scappaticci F A, Fehrenbacher L, Cartwright T et al.. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.  J Surg Oncol. 2005;  91 (3) 173-180
  CrossrefPubMedGoogle Scholar
• 6 Cheon E C, Small Jr W, Strouch M J et al.. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.  J Surg Oncol. 2010;  102 (5) 539-542
  CrossrefPubMedGoogle Scholar
• 7 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 (23) 2335-2342
  CrossrefPubMedGoogle Scholar
• 8 Kabbinavar F F, Schulz J, McCleod M et al.. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 (16) 3697-3705
  CrossrefPubMedGoogle Scholar
• 9 Erinjeri J P, Fong A J, Kemeny N E, Brown K T, Getrajdman G I, Solomon S B. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.  Cancer. 2011;  117 (6) 1296-1301
  CrossrefPubMedGoogle Scholar
• 10 Brown D B, Cardella J F, Sacks D et al.. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.  J Vasc Interv Radiol. 2009;  20 (7, Suppl) 219-226
  CrossrefPubMedGoogle Scholar
• 11 Ahn J, Trost D W, Mitty H A, Sos T A. Pseudoaneurysm formation after catheter dissection of the common hepatic artery: report of two cases.  Am J Gastroenterol. 1997;  92 (4) 696-699
  PubMedGoogle Scholar

Daniel B BrownM.D. 

Division of Interventional Radiology and the Kimmel Cancer Center, Thomas Jefferson University

132 South 10th Street, Suite 766, Philadelphia, PA 19107

Email: daniel.brown@jefferson.edu